Chiral bithiophene-dinitrogen oxygen ligand, preparation method thereof and application of chiral bithiophene-dinitrogen oxygen ligand in asymmetric catalytic reaction
By designing chiral bisthiophene-bis(nitrogen oxide) ligands (BbTh-2NO and BTh-2NO), the problem of low efficiency in the synthesis of chiral drugs in the prior art has been solved, and efficient and economical catalytic effects have been achieved in asymmetric catalytic reactions, especially in the Friedel-Crafts alkylation reaction involving indole, which shows excellent catalytic activity.
Patent Information
- Application Number
- CN202411068131.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-06
AI Technical Summary
Existing technologies struggle to efficiently synthesize chiral drugs, particularly due to the lack of economical and stable dominant chiral ligands in asymmetric catalytic reactions, which impacts the efficiency and cost of chiral drug preparation.
Chiral bisthiophene-bis(nitroxy) ligands (BbTh-2NO and BTh-2NO) were designed and synthesized. These ligands contain bisthiophene and nitroxy groups and can form a six-membered ring coordination with the Lewis acid soft metal palladium. They are used as chiral ligands in asymmetric catalytic reactions and have good air stability and wide applicability.
It achieves efficient and economical catalytic effects in the field of asymmetric catalytic synthesis, is applicable to various substituents, and exhibits excellent catalytic activity and stability. It is suitable for asymmetric catalytic indole-indole-involved Friedel-Crafts alkylation reactions.
Smart Images

Figure CN118978539A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of chiral chemistry and asymmetric catalytic synthesis, in particular to a chiral bithiophene-diazotoxide ligand (BbTh-2NO and BTh-2NO) and a preparation method thereof and application thereof in asymmetric catalytic indole-involved Friedel-Crafts alkylation reaction. Background Art
[0002] Chiral pharmaceuticals are at the forefront of the pharmaceutical industry, and the Nobel Prizes in Chemistry in 2001 and 2021 were awarded to the main contributors to chiral catalysis. There are currently about 2,000 drugs in use in the world, of which chiral drugs account for more than 50%. Among the 250 drugs commonly used in clinical practice, there are as many as 200 chiral drugs.
[0003] The key preparation technology of chiral drugs was selected as one of the "Top Ten Chemical Technology Inventions that Changed the World" proposed by IUPAC. Asymmetric catalysis technology is the most efficient and green way to obtain chiral molecules. One of its core scientific issues is the creation of dominant chiral ligands and catalysts. The design and synthesis of original dominant chiral ligands play a key role in the development of asymmetric catalytic reactions. It is the most attractive and challenging goal in asymmetric catalysis and can provide core technology for the efficient and green synthesis of chiral drugs and candidate drugs. In addition, economically feasible synthetic routes are also crucial for dominant chiral ligands, so that they can be widely used. In particular, N-oxides of amines are highly polar substances, which can be easily prepared by N-oxidation of pyridine compounds or tertiary amines. The oxygen atoms generated in N-oxides belong to electron-rich coordination sites. Therefore, the unique properties of the electron pairs of N-oxides provide opportunities to form complexes with a variety of metals. Some research focuses on the development of new chiral amine N-oxide ligands for metal-catalyzed reactions.
[0004] In tertiary amine-derived N-oxides, if the parent tertiary amine contains three different groups, the nitrogen center on the corresponding N-oxyl group will produce a stable chiral center. In this context, we therefore designed and developed a new type of chiral bithiophene-diazotoxy ligands (BbTh-2NO and BTh-2NO) and tested their application in the asymmetric Friedel-Crafts alkylation of indole. Based on the design and synthesis of the new type of chiral bithiophene-diazotoxy ligands, our design ideas refer to the "eagle" bionic model diagram: the dizotoxy group is likened to the two "eagle" claws, the two phenyl groups are likened to the "eagle" wings, and the bithiophene group is likened to the "eagle" body (such as Figure 1 and Figure 2 shown). Summary of the invention
[0005] The purpose of the present invention is to provide a chiral bithiophene-bis-nitrogen oxide ligand (BbTh-2NO and BTh-2NO) and a preparation method and application thereof. The ligand comprises a bithiophene group and a nitrogen oxide group (the sulfur atom of the bithiophene and the oxygen atom of the nitrogen oxide group belong to electron-rich coordination sites), and can form a six-membered ring coordination with Lewis acid soft metal palladium to generate a chiral ligand metal palladium complex, which is used as a chiral ligand in an asymmetric catalytic reaction. Therefore, it has important application value in the field of asymmetric catalytic synthesis, and its synthesis method is very economical and simple. It also has good air stability, wide applicability, and good compatibility with various substituents.
[0006] The present invention is achieved as follows: a chiral bithiophene-diazolyl ligand (BbTh-2NO and BTh-2NO), characterized in that: the chiral bithiophene-diazolyl ligand BbTh-2NO has a structure as shown in the general formula (I), and the chiral bithiophene-diazolyl ligand BTh-2NO has a structure as shown in the general formula (II);
[0007]
[0008] In the formula, R is hydroxyl or hydrogen; Ar is fluorine, chlorine, bromine, ethyl, tert-butyl, isopropyl, methoxy, methyl or a benzene ring substituted with hydrogen.
[0009] The preparation method of chiral thiophene-diazolyl ligand BbTh-2NO is characterized in that: the corresponding proline amide or hydroxyproline amide 1 and thiophene-dicarboxaldehyde 2 are first subjected to a condensation reaction to generate an intermediate 3, and then the nitrogen atom in the intermediate 3 is subjected to a nitrogen oxidation reaction under the action of an oxidant, meta-chloroperbenzoic acid, to generate the final product chiral thiophene-diazolyl ligand BbTh-2NO.
[0010] The synthetic route is as follows:
[0011]
[0012] The preparation method of chiral bithiophene-diazolyl ligand BTh-2NO is characterized in that: the corresponding proline amide or hydroxyproline amide 1 and bithiophene-bisformaldehyde 2' first undergo condensation reaction to generate an intermediate 3', and then the nitrogen atom in the intermediate 3' undergoes nitrogen oxidation reaction under the action of an oxidant, meta-chloroperbenzoic acid, to generate the final product chiral bithiophene-diazolyl ligand BTh-2NO.
[0013] The synthetic route is as follows:
[0014]
[0015] The present invention also finds the application of chiral thiophene-diazotoxide ligand BbTh-2NO as a ligand in asymmetric catalytic indole-involved Friedel-Crafts alkylation reaction.
[0016] The present invention also finds the application of chiral bithiophene-diazotol ligand BTh-2NO in asymmetric catalytic indole-involved Friedel-Crafts alkylation reaction.
[0017] Our design ideas are:
[0018]
[0019] The mechanism of the asymmetric catalytic Friedel-Crafts alkylation reaction of indole by the chiral thiophene-diazotoxide ligand BbTh-2NO ligand is as follows:
[0020]
[0021] By adopting the above technical scheme, the corresponding proline amide or hydroxyproline amide 1 and thiophene-diformaldehyde 2 first undergo condensation reaction to generate intermediate 3, and then the nitrogen atom in intermediate 3 undergoes nitrogen oxidation reaction under the action of oxidant meta-chloroperbenzoic acid to generate the final product chiral thiophene-bis-nitrogen oxide ligand BbTh-2NO; the corresponding proline amide or hydroxyproline amide 1 and bithiophene-diformaldehyde 2' first undergo condensation reaction to generate intermediate 3', and then the nitrogen atom in intermediate 3' undergoes nitrogen oxidation reaction under the action of oxidant meta-chloroperbenzoic acid to generate the final product chiral bithiophene-bis-nitrogen oxide ligand BTh-2NO. This type of ligand contains a bithiophene group and a nitrogen oxide group (the sulfur atom of bithiophene and the oxygen atom of the nitrogen oxide group belong to electron-rich coordination sites), which can form a six-membered ring coordination with Lewis acid soft metal palladium to generate a chiral ligand metal palladium complex, which is used as a chiral ligand in asymmetric catalytic reactions. Therefore, it has important application value in the field of asymmetric catalytic synthesis, and its synthesis method is very economical and simple. It also has good air stability, wide applicability, and good compatibility with various substituents. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 and Figure 2 The design idea and creative diagram of a chiral bithiophene-bis(N-oxygen) ligand (BbTh-2NO and BTh-2NO) synthesized by the present invention;
[0023] Figure 2 The "eagle" bionic model diagram referred to in the present invention: the dinitrogen oxide group is likened to the two "eagle" claws, the two phenyl groups are likened to the "eagle" wings, and the bithiophene group is likened to the "eagle" body;
[0024] Figure 3 and Figure 4 The spectrum data of the chiral ligand BbTh-1-2NO of the embodiment of the present invention;
[0025] Figure 5 and Figure 6 The spectrum data of the chiral ligand BTh-4-2NO of the embodiment of the present invention; DETAILED DESCRIPTION
[0026] (I) Preparation of chiral thiophene-diazotol ligand BbTh-2NO
[0027]
[0028] Chiral thiophene-diazolyl ligand BbTh-1-2NO: The raw material proline amide 1a (2.5 eq) and thiophene-dicarboxaldehyde (1 eq, 0.78 mmol) 2 were dissolved in an appropriate amount of anhydrous ethanol, refluxed for 12 h, and the reaction solution was treated and purified by column chromatography to obtain a white solid intermediate 3. The intermediate 3 (100 mg, 1 eq) of the second step reaction and m-chloroperbenzoic acid (3.0 eq) were dissolved in an appropriate amount of dichloromethane, reacted at room temperature for 20 min, and the reaction solution was treated and purified by column chromatography to obtain a light yellow solid BbTh-1-2NO; melting point: 232.5-233.4 ° C, [α] D 20 = +7.4 (c 0.50, CHCl3); total yield 61%, >20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 H NMR(CD3OD,400MHz)δ:2.24-2.26(m,2H),2.39-2.45(m,2H),2.50-2.60(m,4H),3.76-3.80(m,2H),3.94-4.01(m ,2H),4.47-4.50(m,2H),7.02(s,2H),7.18-7.22(m,2H),7.30-7.34(m,4H),7.51(d,J=8.0Hz,4H),7.64(s,2H); 13 CNMR(CD3OD,100MHz)δ:22.5,24.1,69.5,76.3,85.2,115.3,122.9,124.4,126.9,128.9,135.3,137.0,140.8,167.2; HRMS(ESI-TOF)m / z:Calcd.for C 30 H 28 N4NaO4S2[M+Na] + :595.1440;Found:595.1433.
[0029] The preparation method of the chiral thiophene-diazotoxide ligands BbTh-2-2NO to BbTh-14-2NO prepared in the examples is the same as that of the chiral ligand BbTh-1-2NO, and the feed ratio is the same as that of the ligand BbTh-1-2NO, and the ligands BbTh-2-2NO to BbTh-14-2NO can be obtained. The reaction yields are shown in Table 1, but it should be emphasized that the examples are intended to illustrate rather than limit the scope of the present invention. The compounds of the present invention are not limited to the contents shown in Table 1.
[0030] Table 1 shows the chemical structure of the chiral thiophene-diazotol ligand BbTh-2NO.
[0031]
[0032] This example prepares the chiral ligand Bbth-2-2NO: light yellow solid, melting point: 249.0-250.3°C; total yield 62%, >20:1dr; nuclear magnetic resonance and high-resolution mass spectrometry test results are as follows: 1 HNMR (CD3OD, 400MHz) δ: 2.47-2.53 (m, 2H), 2.63-2.70 (m, 2H), 3.61 (d, J = 12.8Hz, 2H), 4.12-4.17 (m, 2H), 4.55-4. 58(m,2H),4.63-4.67(m,2H),6.91(s,2H),7.06-7.10(m,2H),7.17-7.21(m,4H),7.31-7.34(m,4H),7.53(s,2H); 13 C NMR (CD3OD, 100MHz) δ: 35.1, 69.9, 75.2, 76.7, 86.0, 115.3, 123.5, 124.9, 127.0, 128.8, 135.0, 135.4, 141.3, 166.8; HRMS (ESI-TOF) m / z: Calcd.for C 30 H 28 N4NaO6S2[M+Na] + :627.1336;Found:627.1329.
[0033] This example prepares the chiral ligand Bbth-3-2NO: light yellow solid, melting point: 230.6-231.7°C; total yield 60%, 17:1dr; nuclear magnetic resonance and high-resolution mass spectrometry test results are as follows: 1H NMR(CD3OD,400MHz)δ:1.13-1.16(m,6H),2.25-2.28(m,2H),2.40-2.46(m,2H),2.54-2.60(m,8H),3.77-3.81(m ,2H),3.94-3.99(m,2H),4.47-4.50(m,2H),6.97(s,2H),7.13-7.20(m,4H),7.40(d,J=8.8Hz,4H),7.63(s,2H); 13 C NMR(CD3OD,100MHz)δ:14.5,22.4,24.1,27.9,69.5,76.2,85.3,123.0,124.3,1 27.4,128.2,132.9,137.1,140.8,143.4,167.2; HRMS(ESI-TOF)m / z:Calcd.forC 34 H 36 N4NaO4S2[M+Na] + :651.2065;Found:651.2059.
[0034] This example prepares the chiral ligand Bbth-4-2NO: light yellow solid, melting point: 226.1-227.6°C, [α] D 20 =-48.4 (c 0.50, CHCl3); total yield 59%, 16:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 H NMR(CD3OD,400MHz)δ:2.40-2.45(m,4H),2.53-2.57(m,2H),2.69-2.76(m,2H),3.71-3.77(m,2H),4.13-4.20(m ,2H),4.57-4.61(m,2H),6.91(s,2H),7.17-7.21(m,2H),7.29-7.34(m,4H),7.48(d,J=7.6Hz,2H),7.67(s,2H); 13 CNMR(CD3OD,100MHz)δ:23.0,24.7,68.8,77.8,85.5,125.6,127.7,130.2,130.6,131.1,132.2,135.2,141.5,167.6; HRMS(ESI-TOF)m / z:Calcd.for C 30 H 26 Cl2N4NaO4S2[M+Na] + :663.0660;Found:663.0651.
[0035] This example prepares the chiral ligand Bbth-5-2NO: light yellow solid, melting point: 223.6-224.4°C, [α] D 20 =-11.2 (c 0.50, CHCl3); total yield 61%, 19:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 H NMR(CD3OD,400MHz)δ:2.15-2.22(m,2H),2.29-2.36(m,2H),2.39-2.53(m,4H),3.65-3.70(m,2H),3 .85-3.93(m,2H),4.38-4.42(m,2H),6.90(s,2H),6.94-6.98(m,4H),7.40-7.43(m,4H),7.56(s,2H); 13 C NMR(CD3OD,100MHz)δ:22.6,24.2,69.4,76.5,85.3,115.5(d,J CF =23.1Hz),124.7,125.5(d,J CF =9.3Hz),131.3,131.4,136.7,141.0,161.7(d,J CF =245.0Hz),167.3; HRMS(ESI-TOF)m / z:Calcd.for C 30 H 26 F2N4NaO4S2[M+Na] + :631.1254;Found:631.1247.
[0036] This example prepares the chiral ligand Bbth-6-2NO: light yellow solid, melting point: 235.6-236.5°C, [α] D 20 =-18.8 (c 0.60, CHCl3); total yield 61%, >20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 HNMR(CD3OD,400MHz)δ:2.21-2.26(m,8H),2.37-2.42(m,2H),2.49-2.59(m,4H),3.75-3.79(m,2H),3.92 -3.99(m,2H),4.46-4.49(m,2H),6.96(s,2H),7.10(d,J=8.4Hz,4H),7.36(d,J=8.4Hz,4H),7.63(s,2H); 13C NMR (CD3OD, 100MHz) δ: 19.6, 22.5, 24.1, 69.5, 76.3, 85.3, 115.6, 122.9, 124.4, 129.4, 132.7, 137.0, 137.1, 140.8, 167.2; HRMS (ESI-TOF) m / z: Calcd.for C 32 H 32 N4NaO4S2[M+Na] + :623.1753;Found:623.1745.
[0037] This example prepares the chiral ligand Bbth-7-2NO: light yellow solid, melting point: 226.0-226.9°C, [α] D 20 =-21.2 (c 0.55, CHCl3); total yield 62%, >20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 HNMR(CD3OD,400MHz)δ:1.01-1.04(m,12H),2.12-2.13(m,2H),2.28-2.32(m,2H),2.41-2.43(m,4H),2.67-2.72(m,2H),3.67-3.6 8(m,2H),3.83-3.85(m,2H),4.35-4.37(m,2H),6.86(d,J=5.6Hz,2H),7.05-7.08(m,4H),7.29-7.33(m,4H),7.52(d,J=6.0Hz,2H); 13 C NMR(CD3OD,100MHz)δ:22.5,22.9,24.1,33.5,69.6,76.2,85.3,115.6,122.9,1 24.4,126.8,133.0,137.2,140.8,147.9,167.2; HRMS(ESI-TOF)m / z:Calcd.for C 36 H 40 N4NaO4S2[M+Na] + :679.2383;Found:679.2378.
[0038] This example prepares the chiral ligand Bbth-8-2NO: light yellow solid, melting point: 234.2-235.5°C, [α] D 20 =-27.7 (c 0.60, CHCl3); total yield 58%, 18:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1H NMR(CD3OD,400MHz)δ:2.22-2.35(m,4H),2.41-2.46(m,2H),2.53-2.59(m,2H),3.65-3.71(m,2H),3.92-3.99 (m,2H),4.45-4.48(m,2H),6.77(s,2H),7.01-7.06(m,2H),7.08-7.13(m,2H),7.24-7.30(m,4H),7.60(s,2H); 13 C NMR(CD3OD,100MHz)δ:22.7,24.3,69.2,76.7,85.7,116.3(d,J CF =19.3Hz),121.7(d,J CF =13.1Hz),124.6,125.0,128.9,130.6(d,J CF =8.2Hz),136.0,141.2,157.8(d,J CF =249.2Hz),167.5; HRMS(ESI-TOF)m / z:Calcd.forC 30 H 26 F2N4NaO4S2[M+Na] + :631.1254;Found:631.1256.
[0039] This example prepares the chiral ligand Bbth-9-2NO: light yellow solid, melting point: 237.5-238.4°C, [α] D 20 =+25.1 (c 0.52, CHCl3); total yield 61%, >20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 HNMR(CD3OD,400MHz)δ:1.24(s,18H),2.24-2.27(m,2H),2.40-2.46(m,2H),2.49-2.60(m,4H),3.78-3.82(m,2H) ),3.94-4.01(m,2H),4.47-4.50(m,2H),6.99(s,2H),7.35(d,J=8.8Hz,4H),7.43(d,J=8.8Hz,4H),7.64(s,2H); 13C NMR (CD3OD, 100MHz) δ: 22.4, 24.0, 30.2, 34.0, 69.6, 76.1, 85.2, 122.4, 124.3, 125.8, 132.7, 137.2, 140.8, 150.1, 167.1; HRMS (ESI-TOF) m / z: Calcd.for C 38 H 44 N4NaO4S2[M+Na] + :707.2693;Found:707.2685.
[0040] This example prepares the chiral ligand Bbth-10-2NO: light yellow solid, melting point: 247.2-248.2°C, [α] D 20 =-0.3 (c 0.50, CHCl3); total yield 61%, 20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 HNMR(CD3OD,400MHz)δ:2.14-2.16(m,2H),2.30-2.36(m,2H),2.40-2.50(m,4H),3.66-3.70(m,2H),3.83-3.90(m ,2H),4.37-4.40(m,2H),6.82-6.87(m,2H),6.97(s,2H),7.18-7.22(m,4H),7.37(d,J=10.4Hz,2H),7.57(s,2H); 13 C NMR(CD3OD,100MHz)δ:22.4,24.1,69.5,76.2,84.7,109.7(d,J CF =26.1Hz),113.2(d,J CF =21.2Hz),117.8,117.9,124.4,130.3(d,J CF =9.1Hz),136.8,136.9(d,J CF =10.1Hz),140.9,162.8(d,J CF =250.1Hz),167.2; HRMS(ESI-TOF)m / z:Calcd.for C 30 H 26 F2N4NaO4S2[M+Na] + :631.1256;Found:631.1256.
[0041] This example prepares the chiral ligand Bbth-11-2NO: light yellow solid, melting point: 246.6-247.2°C, [α]D 20 =-39.3 (c 0.54, CHCl3); total yield 61%, >20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 HNMR(CD3OD,400MHz)δ:2.31-2.35(m,4H),2.42-2.46(m,2H),2.60-2.67(m,2H),3.59-3.65(m ,2H),4.07-4.14(m,2H),4.47-4.51(m,2H),6.83(s,2H),7.09-7.17(m,6H),7.52-7.55(m,4H); 13 C NMR (CD3OD, 100MHz) δ: 23.1, 24.7, 68.7, 78.2, 85.5, 122.1, 125.8, 128.2, 130.8, 131.1, 132.7, 133.4, 134.7, 141.6, 167.5; HRMS (ESI-TOF) m / z: Calcd.forC 30 H 27 Br2N4O4S2[M+H] + :728.9835;Found:728.9833.
[0042] This example prepares the chiral ligand Bbth-12-2NO: light yellow solid, melting point: 238.0-239.1°C, [α] D 20 =-26.2 (c 0.54, CHCl3); total yield 61%, >20:1dr; NMR and high-resolution mass spectrometry test results are as follows: 1 HNMR(CD3OD,400MHz)δ:2.14-2.18(m,2H),2.26-2.31(m,2H),2.39-2.50(m,4H),3.57(s,6H),3.64-3.68(m,2H ),3.83-3.90(m,2H),4.36-4.39(m,2H),6.71(d,J=8.8Hz,4H),6.80(s,2H),7.25(d,J=8.8Hz,4H),7.53(s,2H); 13 CNMR(CD3OD,100MHz)δ:22.5,24.1,54.6,69.4,76.4,85.7,114.0,124.6,125.1,127.7,137.0,140.8,158.7,167.3; HRMS(ESI-TOF)m / z:Calcd.for C 32 H 32N4NaO6S2[M+Na] + :655.1655;Found:655.1653.
[0043] This example prepares the chiral ligand Bbth-13-2NO: light yellow solid, melting point: 235.0-236.5°C, [α] D 20 =-7.6 (c 0.50, CHCl3); total yield 57%, 16:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 HNMR(CD3OD,400MHz)δ:2.10-2.17(m,2H),2.27-2.33(m,2H),2.36-2.49(m,4H),3.64-3.68(m,2H),3.82-3.89(m,2H),4. 37-4.40(m,2H),6.97(s,2H),7.06-7.10(m,2H),7.21(d,J=8.0Hz,2H),7.33-7.35(m,2H),7.57(s,2H),7.72-7.73(m,2H); 13 C NMR(CD3OD,100MHz)δ:22.5,24.2,69.5,76.3,84.7,121.1,122.1,124.6,125.5, 129.6,130.4,130.5,136.7,136.8,141.0,167.2; HRMS(ESI-TOF)m / z:Calcd.for C 30 H 27 Br2N4O4S2[M+H] + :728.9835;Found:728.9834.
[0044] (II) Preparation of chiral bithiophene-diazotol ligand BTh-2NO
[0045]
[0046] Chiral bithiophene-diazolyl ligand BTh-1-2NO: The raw material proline amide 1a (2.5eq) and bithiophene-dicarboxaldehyde (1eq, 0.78mmol) 2′ were dissolved in an appropriate amount of anhydrous ethanol, refluxed for 12h, and the reaction solution was treated and purified by column chromatography to obtain a white solid intermediate 3′. The intermediate 3′ (100mg, 1eq) of the second step reaction and m-chloroperbenzoic acid (3.0eq) were dissolved in an appropriate amount of dichloromethane, reacted at room temperature for 20min, and the reaction solution was treated and purified by column chromatography to obtain a light yellow solid BTh-1-2NO, melting point: 247.0-247.9℃, total yield 37%, >20:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 H NMR(CD3OD,400MHz)δ:2.58-2.64(m,2H),2.72-2.79(m,2H),3.66(d,J=12.8Hz,2H),4.21-4.26(m,2H),4.68(s,2H) ,4.73-4.77(m,2H),6.95(s,2H),7.12(d,J=2.8Hz,2H),7.18-7.22(m,2H),7.29-7.33(m,6H),7.40(d,J=7.6Hz,4H); 13 C NMR (CD3OD, 100MHz) δ: 35.1, 69.9, 74.9, 77.0, 85.8, 123.3, 123.8, 127.0, 128.8, 130.6, 133.7, 135.0, 141.8, 166.9; HRMS (ESI-TOF) m / z: Calcd.for C 32 H 31 N4O6S2[M+H] + :631.1676;Found:631.1667.
[0047] The preparation method of the chiral bithiophene-diazolyl ligand BTh-1-2NO to BTh-10-2NO prepared in the examples is the same as that of the chiral bithiophene-diazolyl ligand BTh-1-2NO, and the feed ratio is the same as that of the ligand BTh-1-2NO, and the ligand BTh-1-2NO to BTh-10-2NO can be obtained. The reaction yield is shown in Table 2, but it should be emphasized that the examples are intended to illustrate rather than limit the scope of the present invention. The compounds of the present invention are not limited to the contents shown in Table 2.
[0048] Table 2 shows the chemical structure of the chiral bithiophene-diazotol ligand BTh-2NO.
[0049]
[0050] This example prepares the chiral ligand BTh-2-2NO: light yellow solid, total yield 25%, 14:1dr; nuclear magnetic resonance and high-resolution mass spectrometry test results are as follows: 1 HNMR(CD3OD,400MHz)δ:2.27-2.32(m,2H),2.38-2.47(m,2H),2.49-2.54(m,2H),2.59-2.65(m,2H),3.72-3.77(m,2H),3. 92-3.99(m,2H),4.46-4.50(m,2H),7.00(s,2H),7.20-7.24(m,4H),7.30-7.32(m,4H),7.40(d,J=8.4Hz,2H),7.70(s,2H); 13 C NMR(CD3OD,100MHz)δ:22.5,24.1,69.0,76.4,84.3,120.9,122.8,123.9,126.7, 130.1,132.0,133.0,134.4,136.6,141.1,167.3; HRMS(ESI-TOF)m / z:Calcd.forC 32 H 29 Cl2N4O4S2[M+H] + :667.1002;Found:667.0993.
[0051] This example prepares the chiral ligand BTh-3-2NO: light yellow solid, melting point: 245.9-246.6°C, total yield 36%, >20:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 HNMR(CD3OD,400MHz)δ:1.13(s,6H),1.14(s,6H),2.22-2.25(m,2H),2.38-2.45(m,2H),2.50-2.61(m,4H),2.78-2.85(m,2H),3.7 6-3.80(m,2H),3.92-3.99(m,2H),4.43-4.46(m,2H),6.87(d,J=3.6Hz,2H),6.92(s,2H),7.21-7.23(m,6H),7.46(d,J=8.4Hz,4H); 13 CNMR (CD3OD, 100MHz) δ: 22.5, 23.0, 24.1, 33.6, 69.4, 76.2, 84.8, 123.0, 123.8, 127.0, 132.7, 133.0, 140.5, 148.0, 167.2; HRMS (ESI-TOF) m / z: Calcd.for C 38 H43 N4O4S2[M+H] + :683.2720;Found:683.2721.
[0052] This example prepares the chiral ligand BTh-4-2NO: light yellow solid, melting point: 231.1-232.4°C, total yield 34%, >20:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 HNMR(CD3OD,400MHz)δ:2.25-2.26(m,2H),2.28(s,6H),2.39-2.45(m,2H),2.49-2.63(m,4H),3.74-3.79(m,2H),3.92- 3.99(m,2H),4.45-4.48(m,2H),6.94(s,2H),7.04(d,J=7.2Hz,2H),7.15-7.17(m,2H),7.20-7.28(m,6H),7.36(s,2H); 13 C NMR(CD3OD,100MHz)δ:20.0,22.5,24.1,69.1,76.4,84.8,120.1,123.6,123.8,127 .7,128.8,132.6,132.9,135.1,139.2,140.8,167.3; HRMS(ESI-TOF)m / z:Calcd.for C 34 H 35 N4O4S2[M+H] + :627.2091;Found:627.2085.
[0053] This example prepares the chiral ligand BTh-5-2NO: light yellow solid, melting point: 232.9-233.4°C, total yield 31%, >20:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 HNMR(CD3OD,400MHz)δ:2.24-2.36(m,14H),2.45-2.55(m,4H),2.76-2.85(m,2H),3.48-3.56(m,2H),3.86-3 .92(m,2H),4.52-4.56(m,2H),6.86(s,2H),6.95-7.00(m,6H),7.04(d,J=7.2Hz,2H),7.19(d,J=7.6Hz,2H); 13C NMR(CD3OD,100MHz)δ:17.6,17.8,23.4,25.2,66.1,80.0,85.4,121.6,127.0,128.2,1 28.5,128.8,131.1,134.2,135.5,138.5,143.3,167.6; HRMS(ESI-TOF)m / z:Calcd.for C 36 H 38 N4NaO4S2[M+Na] + :677.2217;Found:677.2213.
[0054] This example prepares the chiral ligand BTh-6-2NO: light yellow solid, melting point: 223.7-224.4°C, total yield 30%, 20:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 H NMR(CD3OD,400MHz)δ:2.29-2.34(m,2H),2.38-2.45(m,2H),2.50-2.66(m,4H),3.72-3.78(m,2H),3.94-4.01(m,2H) ,4.47-4.50(m,2H),6.93(s,2H),7.08-7.12(m,4H),7.19(d,J=4.0Hz,2H),7.31(d,J=3.6Hz,2H),7.49-7.52(m,4H); 13 C NMR(CD3OD,100MHz)δ:22.5,24.2,68.9,76.6,84.9,115.5(d,J CF =23.4Hz),123.7,125.6(d,J CF =8.3Hz),131.3,132.1,133.2,141.2,161.2(d,J CF =245.1Hz),167.3; HRMS(ESI-TOF)m / z:Calcd.for C 32 H 28 F2N4NaO4S2[M+Na] + :657.1405;Found:657.1396.
[0055] This example prepares the chiral ligand BTh-7-2NO: light yellow solid, melting point: 224.0-225.4°C, total yield 31%, 18:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1H NMR(CD3OD,400MHz)δ:1.12-1.16(m,3H),2.25-2.30(m,2H),2.39-2.45(m,2H),2.51-2.62(m,8H),3.74-3.79(m,2H),3.92-3. 99(m,2H),4.44-4.47(m,2H),6.91(s,2H),7.11(d,J=8.0Hz,2H),7.17(d,J=8.8Hz,4H),7.25-7.27(m,2H),7.38-7.41(m,4H); 13 C NMR(CD3OD,100MHz)δ:14.5,22.5,24.1,27.9,69.2,76.4,84.9,123.1,123.8,1 28.3,132.6,132.8,133.0,140.8,143.5,167.2; HRMS(ESI-TOF)m / z:Calcd.for C 36 H 38 N4NaO4S2[M+Na] + :677.2217;Found:677.2207.
[0056] This example prepares the chiral ligand BTh-8-2NO: light yellow solid, melting point: 237.8-238.4°C, total yield 30%, 17:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 H NMR(CD3OD,400MHz)δ:2.29(s,6H),2.36-2.43(m,4H),2.47-2.54(m,2H),2.67-2.75(m,2H),3.60-3.67(m,2H),3.91-3.98 (m,2H),4.55-4.59(m,2H),6.89(s,2H),7.05(d,J=4.0Hz,2H),7.10-7.13(m,2H),7.17-7.20(m,6H),7.24(d,J=4.0Hz,2H); 13 CNMR(CD3OD,100MHz)δ:17.3,23.0,24.9,67.8,78.7,86.1,122.5,126.4,128.6, 130.1,131.0,132.8,134.3,136.6,142.3,167.4; HRMS(ESI-TOF)m / z:Calcd.for C 34 H 34 N4NaO4S2[M+Na] + :649.1905;Found:649.1888.
[0057] This example prepares the chiral ligand BTh-9-2NO: light yellow solid, melting point: 235.6-236.4°C, total yield 30%, 20:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 H NMR(CD3OD,400MHz)δ:2.37-2.44(m,4H),2.49-2.56(m,2H),2.71-2.78(m,2H),3.66-3.72(m,2H),4.06- 4.13(m,2H),4.57-4.60(m,2H),6.88(s,2H),7.13(d,J=3.6Hz,2H),7.22-7.36(m,8H),7.45-7.48(m,2H); 13 CNMR(CD3OD,100MHz)δ:23.1,24.8,68.2,78.2,85.3,123.0,127.8,130.1,130.2 ,130.6,130.8,131.2,132.3,134.4,142.4,167.7; HRMS(ESI-TOF)m / z:Calcd.for C 32 H 28 Cl2N4NaO4S2[M+Na] + :689.0817;Found:689.0812.
[0058] This example prepares the chiral ligand BTh-10-2NO: light yellow solid, melting point: 221.1-222.4°C, total yield 31%, 12:1dr; the results of nuclear magnetic resonance and high-resolution mass spectrometry tests are as follows: 1 H NMR(CD3OD,400MHz)δ:2.25-2.30(m,2H),2.39-2.45(m,2H),2.49-2.64(m,4H),3.72-3.77(m,2H),3.91-3.98(m,2H),4.46-4.50(m,2 H),7.00(s,2H),7.15-7.17(m,2H),7.22-7.26(m,2H),7.30(d,J=4.0Hz,2H),7.34-7.37(m,2H),7.43-7.46(m,2H),7.84-7.85(m,2H); 13C NMR(CD3OD,100MHz)δ:22.5,24.2,69.0,76.4,84.3,121.3,122.1,123.9,125.7, 129.7,130.4,132.0,133.1,136.7,141.1,167.3; HRMS(ESI-TOF)m / z:Calcd.for C 32 H 28 Br2N4NaO4S2[M+Na] + :776.9811;Found:776.9812.
[0059] (III) Application of chiral bithiophene-diazolyl ligands (BbTh-2NO and BTh-2NO) in asymmetric catalytic Friedel-Crafts alkylation of indole
[0060] The chiral bithiophene-diazolyl ligands (BbTh-2NO and BTh-2NO) of formula (1) of the present invention contain bithiophene groups and nitroxide groups (the sulfur atom of bithiophene and the oxygen atom of the nitroxide group belong to electron-rich coordination sites), which can form a six-membered ring coordination with Lewis acid soft metal palladium to generate a chiral ligand metal palladium complex, and are used as a dominant chiral ligand in the Friedel-Crafts alkylation reaction of indole in asymmetric catalysis. However, it should be emphasized that the chiral bithiophene-diazolyl ligands (BbTh-2NO and BTh-2NO) of the present invention are not limited to being used as chiral ligands in the Friedel-Crafts alkylation reaction of indole in asymmetric catalysis.
[0061] Example 1: Application of chiral thiophene-diazolyl ligand BbTh-2NO with various substituents in the asymmetric catalytic Friedel-Crafts alkylation of indole 4a and enone lactam 5a
[0062] In order to demonstrate the application value of the developed chiral ligand BbTh-2NO in asymmetric catalytic systems, we selected the Friedel-Crafts alkylation reaction of indole 4a and enone lactam 5a as the template reaction, and selected compounds BbTh-1-2NO~BbTh-13-2NO as chiral thiophene-diazolyl ligands to in situ generate chiral complexes with Lewis acid Pd(CH2CO2)2 to verify the asymmetric catalytic effect of the chiral ligand BbTh-2NO (Table 3).
[0063] Table 3 shows the application of chiral ligand BbTh-2NO with various substituents in asymmetric catalytic reactions
[0064]
[0065] Experimental conclusion: The asymmetric catalytic Friedel-Crafts alkylation template reaction of indole 4a and enone lactam 5a was selected as the evaluation index. The experimental results show that the chiral ligands BbTh-1-2NO~BbTh-13-2NO with various substituents shown in formula (1) generate chiral complexes in situ with Lewis acid Pd(CH2CO2)2, which show asymmetric catalytic effects in the Friedel-Crafts alkylation reaction of indole 4a and enone lactam 5a, and can be developed into a new advantageous chiral thiophene-diazotoxide ligand BbTh-2NO, which is worthy of further in-depth study.
[0066] Example 2: Application of chiral ligand BbTh-1-2NO in asymmetric catalytic Friedel-Crafts alkylation of various substituted indoles 4 and various substituted enone lactams 5
[0067] In order to demonstrate the application value of the developed chiral ligand BbTh-1-2NO in asymmetric catalytic systems, we selected the Friedel-Crafts alkylation reaction of indoles 4 with various substituents and enone lactams 5 with various substituents as the template reaction to verify the catalytic effect of the chiral ligand BbTh-1-2NO (Table 4).
[0068] Table 4 shows the application of chiral ligand BbTh-1-2NO in asymmetric catalytic reactions
[0069]
[0070] Experimental conclusion: The asymmetric catalytic Friedel-Crafts alkylation template reaction of various substituted indoles 4 and various substituted enone lactams 5 was selected as the evaluation index. The experimental results show that the chiral ligand BbTh-1-2NO represented by formula (1) generates a chiral complex in situ with Lewis acid Pd(CH2CO2)2, and shows asymmetric catalytic effect in the Friedel-Crafts alkylation reaction of various substituted indoles 4 and various substituted enone lactams 5. It can be developed into a new dominant chiral ligand and is worthy of further in-depth study.
[0071] Example 3: Application of chiral bithiophene-diazotol ligand BTh-2NO with various substituents in the asymmetric catalytic Friedel-Crafts alkylation of indole 4a and enone lactam 5a
[0072] In order to demonstrate the application value of the developed chiral ligand BTh-2NO in asymmetric catalytic systems, we selected the Friedel-Crafts alkylation reaction of indole 4a and enone lactam 5a as the template reaction, and selected compounds BTh-1-2NO~BTh-10-2NO as chiral bithiophene-diazolyl ligands to in situ generate chiral complexes with Lewis acid Pd(CH2CO2)2 to verify the asymmetric catalytic effect of the chiral ligand BTh-2NO (Table 5).
[0073] Table 5 shows the application of chiral ligand BTh-2NO with various substituents in asymmetric catalytic reactions
[0074]
[0075] Experimental conclusion: The asymmetric catalytic Friedel-Crafts alkylation template reaction of indole 4a and enone lactam 5a was selected as the evaluation index. The experimental results show that the chiral ligands BTh-1-2NO~BTh-10-2NO with various substituents shown in formula (1) in situ generate chiral complexes with Lewis acid Pd(CH2CO2)2, which show asymmetric catalytic effects in the Friedel-Crafts alkylation reaction of indole 4a and enone lactam 5a, and can be developed into a new advantageous chiral bithiophene-diazotoxide ligand BTh-2NO, which is worthy of further in-depth study.
Claims
1. A chiral bithiophene-diazotol ligand BbTh-2NO and BTh-2NO, characterized in that: The chiral bithiophene-diazolyl ligand BbTh-2NO has a structure as shown in the general formula (I), and the chiral bithiophene-diazolyl ligand BTh-2NO has a structure as shown in the general formula (II); In the formula, R is hydroxyl or hydrogen; Ar is fluorine, chlorine, bromine, ethyl, tert-butyl, isopropyl, methoxy, methyl or a benzene ring substituted with hydrogen; The chiral thiophene-diazotol ligand BbTh-2NO is specifically one of the following structural formulas: Among them, the chiral bithiophene-diazotol ligand BTh-2NO is specifically one of the following structural formulas:
2. A method for preparing the chiral thiophene-diazotol ligand BbTh-2NO as claimed in claim 1, characterized in that: The corresponding proline amide or hydroxyproline amide 1 first undergoes a condensation reaction with thiophene-dicarboxaldehyde 2 to generate an intermediate 3, and then the nitrogen atom in the intermediate 3 undergoes a nitrogen oxidation reaction under the action of an oxidant, meta-chloroperbenzoic acid, to generate the final product, a chiral thiophene-diazotoxy ligand BbTh-2NO. The synthetic route is as follows:
3. A method for preparing the chiral bithiophene-diazotol ligand BTh-2NO as claimed in claim 1, characterized in that: The corresponding proline amide or hydroxyproline amide 1 first undergoes a condensation reaction with bithiophene-bisformaldehyde 2' to generate an intermediate 3', and then the nitrogen atom in the intermediate 3' undergoes a nitrogen oxidation reaction under the action of an oxidant, meta-chloroperbenzoic acid, to generate the final product, a chiral bithiophene-bis-nitrogen oxide ligand BTh-2NO. The synthetic route is as follows:
4. A use of the chiral thiophene-diazotoxide ligand BbTh-2NO as claimed in claim 1 as a ligand in asymmetric catalytic Friedel-Crafts alkylation reaction involving indole.
5. Use of the chiral bithiophene-diazotol ligand BTh-2NO as claimed in claim 1 in asymmetric catalytic Friedel-Crafts alkylation reaction involving indole.
